Sugi Predict

Sugi Predict / Compounds / SCHEMBL204119

SCHEMBL204119

SCHEMBL204119

CC1(c2ccc(Br)cc2)NC(=O)NC1=O

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 1/20 0.51
▸ MEN1 O00255 1/20 0.51
▸ KMT2A Q03164 1/20 0.51
▸ TNKS O95271 1/20 0.47
▸ MMP2 P08253 3/20 0.39
▸ MMP9 P14780 2/20 0.39
▸ AKR1B1 P15121 1/20 0.39
▸ HTR6 P50406 1/20 0.38
▸ ADAM17 P78536 1/20 0.38
▸ TAAR1 Q96RJ0 1/20 0.38
▸ MMP13 P45452 1/20 0.37
▸ ADAMTS5 Q9UNA0 1/20 0.37
▸ CNR1 P21554 2/20 0.37
▸ CACNA1F O60840 1/20 0.37
▸ ALDH1A1 P00352 1/20 0.37
▸ MAPT P10636 1/20 0.37
▸ CYP2C9 P11712 1/20 0.37
▸ HTR2A P28223 1/20 0.37
▸ HRH1 P35367 1/20 0.37
▸ SCN1A P35498 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6135313 1.00 LMNA (0.51) LMNAMEN1KMT2ATNKSMMP2
SCHEMBL4385865 1.00 LMNA (0.51) LMNAMEN1KMT2ATNKSMMP2
SCHEMBL542561 0.82 LMNA (0.53) LMNAMEN1KMT2ATNKSMMP2
SCHEMBL20134878 0.82 LMNA (0.53) LMNAMEN1KMT2ATNKSMMP2
SCHEMBL542817 0.81 LMNA (0.51) LMNAMEN1KMT2ATNKSMMP2
SCHEMBL17054772 0.81 MEN1 (0.55) LMNAMEN1KMT2ATNKSMMP2
SCHEMBL7099930 0.81 LMNA (0.51) LMNAMEN1KMT2ATNKSMMP2
SCHEMBL17570773 0.81 LMNA (0.51) LMNAMEN1KMT2ATNKSMMP2
SCHEMBL10131744 0.81 LMNA (0.51) LMNAMEN1KMT2ATNKSMMP2
SCHEMBL17055125 0.81 MEN1 (0.55) LMNAMEN1KMT2ATNKSMMP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11242344-B2 (4-hydroxypyrrolidin-2-yl)-heterocyclic compounds and methods of use thereof GENENTECH, INC. (US) 2022-02-08 — — US disclosed
US-11242344-B2 (4-hydroxypyrrolidin-2-yl)-heterocyclic compounds and methods of use thereof GENENTECH, INC. (US) 2022-02-08 — — US disclosed
US-20210309660-A1 (4-HYDROXYPYRROLIDIN-2-YL)-HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF GENENTECH INC (US) 2021-10-07 — — US disclosed
US-20210309660-A1 (4-HYDROXYPYRROLIDIN-2-YL)-HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF GENENTECH INC (US) 2021-10-07 — — US disclosed
CN-106588890-B Antiviral compounds 吉利德制药有限责任公司 2020-11-27 — — CN disclosed
EP-3700901-A1 (4-HYDROXYPYRROLIDIN-2-YL)-HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF Genentech, Inc. (US) 2020-09-02 — — EP disclosed
EP-3626716-A1 ANTIVIRAL COMPOUNDS Gilead Pharmasset LLC (US) 2020-03-25 — — EP disclosed
US-9981955-B2 Antiviral compounds GILEAD PHARMASSET LLC (US) 2018-05-29 — — US disclosed
EP-3309157-A1 ANTIVIRAL COMPOUNDS Gilead Pharmasset LLC (US) 2018-04-18 — — EP disclosed
EP-3309157-A1 ANTIVIRAL COMPOUNDS Gilead Pharmasset LLC (US) 2018-04-18 — — EP disclosed
EP-0823898-B1 HYDANTOINE DERIVATIVES AS INTERMEDIATE PRODUCTS FOR ACTIVE PHARMACEUTICAL AGENTS HOECHST AG (DE) 2003-02-26 — — EP disclosed
US-6423712-B1 2,4-Substituted imidazolidine derivatives, their preparation, their use and pharmaceutical preparations comprising them AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2002-07-23 — — US disclosed
US-6294562-B1 AMIDINO COMPOUNDS WITH AMIDO ESTERS CARDIOVASCULAR SYSTEM, DISEASES OF THE CORONARY VASCULAR SYSTEM OR THE CEREBROVASCULAR SYSTEM, OR PERIPHERAL ARTERIAL VASCULAR DISEASE HOECHST AKTIENGESELLSCHAFT (DE) 2001-09-25 — — US disclosed
US-6018053-A Process for the preparation of chiral, nonracemic (4-aryl-2,5-dioxoimidazolidin-1-yl) acetic acids HOECHST AKTIENGESELLSCHAFT (DE) 2000-01-25 — — US disclosed
US-5939556-A Hydantoin compounds, salts thereof, processes for their preparation, and processes for preparing pharmaceutically active compounds comprising them HOECHST AKTIENGESELLSCHAFT (DE) 1999-08-17 — — US disclosed
CN-1218047-A Novel imidazolidine derivatives, their preparation, their use and pharmaceutical preparations comprising them HOECHST MARION ROUSSEL DE GMBH (DE) 1999-06-02 — — CN disclosed
EP-0823898-A1 HYDANTOINE DERIVATIVES AS INTERMEDIATE PRODUCTS FOR ACTIVE PHARMACEUTICAL AGENTS HOECHST AKTIENGESELLSCHAFT (DE) 1998-02-18 — — EP disclosed
EP-0816343-A1 Process for the preparation of chiral, non-racemic (4-aryl-2,5-dioxoimidazolin-1-yl)-acetic acids HOECHST AKTIENGESELLSCHAFT (DE) 1998-01-07 — — EP disclosed
EP-0811616-A1 Salts of 3-(2-(4-(4-(Amino-imino-methyl)-phenyl)-4-methyl-2,5-dioxo-imidazolidin-1-yl)-acetylamino)-3-phenyl-propionic acid ethylester HOECHST AKTIENGESELLSCHAFT (DE) 1997-12-10 — — EP disclosed
WO-1996033976-A1 HYDANTOINE DERIVATIVES AS INTERMEDIATE PRODUCTS FOR ACTIVE PHARMACEUTICAL AGENTS HOECHST AKTIENGESELLSCHAFT (DE) 1996-10-31 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210309660-A1 (4-HYDROXYPYRROLIDIN-2-YL)-HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF VHL, MDM2, CUL2 LMNA 2919/4885MEN1 2547/4885KMT2A 1816/4885
US-11242344-B2 (4-hydroxypyrrolidin-2-yl)-heterocyclic compounds and methods of use thereof VHL, MDM2, CUL2 LMNA 2919/4885MEN1 2547/4885KMT2A 1816/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.